Late luteal phase administration of RU486 for three successive cycles does not disrupt bleeding patterns or ovulation
- PMID: 3119656
- DOI: 10.1210/jcem-65-6-1272
Late luteal phase administration of RU486 for three successive cycles does not disrupt bleeding patterns or ovulation
Abstract
RU486, a 19-nor steroid, binds with high affinity to the receptors for progesterone and glucocorticoids, blocking the actions of these hormones on their target tissues. We conducted studies to determine whether RU486 administered at the end of the luteal phase would disturb the menstrual rhythm, ovulation, or hormonal parameters in the treatment and post-treatment cycles. The first study was done in six surgically sterilized women during two consecutive cycles. RU486 [17 beta-hydroxy-11 beta-(4-dimethylaminophenyl)17 alpha-(1-propynyl)estra-4,9-dien-3-one; 100 mg/day] was given for 4 consecutive days, commencing on days 23-27 of the first cycle. Menstrual bleeding occurred by the second day of RU486 administration in all women and was indistinguishable from their usual bleeding pattern. The onset of this bleeding was advanced by RU486 administration, since it entailed shortening of the luteal phase with prolongation of the following follicular phase. Serum LH, FSH, estradiol, and progesterone levels were normal in five of the six women in both the treatment and posttreatment cycles. The second study was conducted in 10 women who were not exposed to the risk of pregnancy. RU486 (100 mg/day) was given for 4 consecutive days, commencing 4 days before their expected menses for 3 successive cycles, preceded and followed by 2 placebo-treated cycles. Bleeding patterns were indistinguishable during the RU486 and placebo cycles. Late luteal phase administration of RU486 consistently produced menstrual bleeding within 1-3 days of drug administration. Daily early morning urinary LH excretion in 6 women and estrone glucuronide and pregnanediol glucuronide excretion in 5 women during both placebo and RU486 cycles were consistent with luteinization, suggesting ovulation and appropriate corpus luteum function. We conclude that RU486 has no major effect on menstrual cycle events if given at the time of the natural progesterone withdrawal that occurs before menses in nonpregnant women.
Similar articles
-
Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle.J Clin Endocrinol Metab. 1988 Mar;66(3):508-17. doi: 10.1210/jcem-66-3-508. J Clin Endocrinol Metab. 1988. PMID: 2832438
-
Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486.J Clin Endocrinol Metab. 1987 Dec;65(6):1135-40. doi: 10.1210/jcem-65-6-1135. J Clin Endocrinol Metab. 1987. PMID: 2824550
-
Effects of the antiprogesterone steroid RU 486 during midluteal phase in normal women.J Clin Endocrinol Metab. 1985 Sep;61(3):484-9. doi: 10.1210/jcem-61-3-484. J Clin Endocrinol Metab. 1985. PMID: 2991322
-
Effect of mifepristone on inhibition of ovulation and induction of luteolysis.Hum Reprod. 1994 Jun;9 Suppl 1:69-76. doi: 10.1093/humrep/9.suppl_1.69. Hum Reprod. 1994. PMID: 7962472 Review.
-
Response to the antiprogestagen RU 486 (mifepristone) during early pregnancy and the menstrual cycle in women.J Reprod Fertil Suppl. 1989;37:253-60. J Reprod Fertil Suppl. 1989. PMID: 2681741 Review.
Cited by
-
Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.Drugs. 1993 Mar;45(3):384-409. doi: 10.2165/00003495-199345030-00007. Drugs. 1993. PMID: 7682909 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources